DIN 02510049 — DUPIXENT 300 MG
DUPIXENT is a solution of Dupilumab marketed by SANOFI-AVENTIS CANADA INC. The full Dupilumab monograph covers indications, dosing, interactions and counselling for every strength and manufacturer.
- DIN
- 02510049
- Brand name
- DUPIXENT
- Active ingredient
- Dupilumab
- Strength
- 300 MG
- Dosage form
- SOLUTION
- Route
- SUBCUTANEOUS
- Manufacturer
- SANOFI-AVENTIS CANADA INC
- Health Canada status
- MARKETED
- Drug class
- Immunomodulator (interleukin-4/13 receptor alpha antagonist)
Product data from the Health Canada Drug Product Database, synced . Verify the live status at Health Canada.
Other Dupilumab products
| DIN | Brand | Strength | Form | Manufacturer | Status |
|---|---|---|---|---|---|
| 02492504 | DUPIXENT | 200 MG | SOLUTION | SANOFI-AVENTIS CANADA INC | MARKETED |
| 02524252 | DUPIXENT | 200 MG | SOLUTION | SANOFI-AVENTIS CANADA INC | MARKETED |
| 02470365 | DUPIXENT | 300 MG | SOLUTION | SANOFI-AVENTIS CANADA INC | MARKETED |